Cue biopharma to present at the guggenheim i&i spotlight series

Boston, july 11, 2022 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific t cells directly within the patient's body, announced today that it will take part in a fireside chat at the guggenheim i&i spotlight series – treg-based therapies being held july 12–13, 2022.
CUE Ratings Summary
CUE Quant Ranking